A Muscle Hybrid Promoter as a Novel Tool for Gene Therapy
Gene therapy is a promising strategy to cure rare diseases. The lack of regulatory sequences ensuring specific and robust expression in skeletal and cardiac muscle is a substantial limitation of gene therapy efficiency targeting the muscle tissue. Here we describe a novel muscle hybrid (MH) promoter...
Main Authors: | Katarzyna Piekarowicz, Anne T. Bertrand, Feriel Azibani, Maud Beuvin, Laura Julien, Magdalena Machowska, Gisèle Bonne, Ryszard Rzepecki |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-12-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050119300981 |
Similar Items
-
Regulation of lamin properties and functions: does phosphorylation do it all?
by: Magdalena Machowska, et al.
Published: (2015-01-01) -
Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy Treatment
by: Katarzyna Piekarowicz, et al.
Published: (2019-01-01) -
Generation of one control and four iPSCs clones from patients with Emery-Dreifuss muscular dystrophy type 1
by: Magdalena Machowska, et al.
Published: (2021-08-01) -
Emerin Is Required for Proper Nucleus Reassembly after Mitosis: Implications for New Pathogenetic Mechanisms for Laminopathies Detected in EDMD1 Patients
by: Magda Dubińska-Magiera, et al.
Published: (2019-03-01) -
Laminopathies: what can humans learn from fruit flies
by: Marta Pałka, et al.
Published: (2018-07-01)